Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Venture Financing 12
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Partnerships 16
Aeglea BioTherapeutics Enters into Agreement with Merck 16
Licensing Agreements 17
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
AECase Enters into Licensing Agreement with University of Texas at Austin 18
Equity Offering 19
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 19
Aeglea BioTherapeutics Raises USD54.8 million in IPO 20
Aeglea BioTherapeutics Inc – Key Competitors 21
Aeglea BioTherapeutics Inc – Key Employees 22
Aeglea BioTherapeutics Inc – Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Financial Announcements 24
Nov 07, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results 24
Aug 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Second Quarter 2017 Financial Results 25
May 09, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports First Quarter 2017 Financial Results 26
Mar 23, 2017: Aeglea BioTherapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2016 Financial Results 27
Nov 09, 2016: Aeglea BioTherapeutics Provides Corporate Update and Reports Third Quarter 2016 Financial Results 29
Aug 09, 2016: Aeglea BioTherapeutics Announces Second Quarter 2016 Financial Results 31
May 19, 2016: Aeglea BioTherapeutics Announces First Quarter 2016 Financial Results 33
Corporate Communications 34
Jul 20, 2017: Aeglea BioTherapeutics Announces Leadership Change 34
Jul 10, 2017: Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer 35
Feb 16, 2017: Aeglea BioTherapeutics Appoints Dr. Suzanne Bruhn to Board of Directors 36
May 16, 2016: Aeglea BioTherapeutics Names Dr. Sandra Rojas-Caro as Chief Medical Officer 37
Mar 15, 2016: Aeglea BioTherapeutics Appoints Dr. Anthony Quinn to Board of Directors 38
Product News 39
11/08/2016: Aeglea BioTherapeutics to Present a Poster at the Society for Immunotherapy of Cancer 2016 Annual Meeting Suggesting Potential for AEB1102 Combination Therapy with Immuno-Oncology Checkpoint Inhibitors 39
Product Approvals 40
May 23, 2016: Aeglea BioTherapeutics Receives FDA Fast Track Designation for AEB1102 for the Treatment of Patients with Hyperargininemia Secondary to Arginase I Deficiency 40
Mar 14, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of its Investigational New Drug Application for AEB1102 for the Treatment of Hematological Malignancies 41
Jan 07, 2016: Aeglea BioTherapeutics Announces FDA Acceptance of Its Investigational New Drug Application for AEB1102 for the Treatment of Arginase I Deficiency 42
Clinical Trials 43
Sep 15, 2016: Aeglea BioTherapeutics Doses First Patients in Phase 1 Trial of AEB1102 for the Treatment of Arginase I Deficiency 43
Aug 29, 2016: Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies 44
Jul 18, 2016: Aeglea BioTherapeutics Provides Update on AEB1102 Clinical Program in Rare Diseases and Cancer 45
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aeglea BioTherapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Aeglea BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aeglea Biotherapeutics Acquires In-Process R&D Assets from GMA Technologies 11
Aeglea BioTherapeutics Raises USD44 Million in Series B Financing 12
Aeglea BioTherapeutics Raises Additional USD1 Million in Series A Venture Financing 14
Aeglea BioTherapeutics Raises US$5.1 Million In Venture Financing 15
Aeglea BioTherapeutics Enters into Agreement with Merck 16
AEMase Enters into Licensing Agreement with University of Texas at Austin 17
AECase Enters into Licensing Agreement with University of Texas at Austin 18
Aeglea BioTherapeutics Prices Public Offering of Shares for USD12.3 Million 19
Aeglea BioTherapeutics Raises USD54.8 million in IPO 20
Aeglea BioTherapeutics Inc, Key Competitors 21
Aeglea BioTherapeutics Inc, Key Employees 22
Aeglea BioTherapeutics Inc, Subsidiaries 23